Company: BSX
Filing Date: 2025-05-01
Form Type: 10-Q
Source: 0000885725-25-000026
Chunk: 69

Company: BOSTON SCIENTIFIC CORP
Filing Date: 2025-05-01
Form: 10-Q
Item: Part I, Item 1
Chunk 69
---
, compared to the prior year period. During the first quarter of 2025, this increase included operational net sales growth of 6.8 percent and the negative impact of 90 basis points from foreign currency fluctuations, compared to the prior year period.

Operational net sales growth during the first quarter of 2025 was primarily driven by our spinal cord stimulation (SCS) systems and our Intracept™ Intraosseous Nerve Ablation System.

35

Cardiovascular

Cardiology

Our Cardiology business develops and manufactures devices and medical technologies for diagnosing and treating a variety of diseases and abnormalities of the heart. Net sales of Cardiology products of $2.429 billion during the first quarter of 2025 represented 52 percent of our consolidated net sales. Cardiology net sales increased $558 million, or 29.8 percent, during the first quarter of 2025, compared to the prior year period. During the first quarter of 2025, this increase included operational net sales growth of 31.2 percent and the negative impact of 140 basis points from foreign currency fluctuations, compared to the prior year period. 

Operational net sales growth was primarily driven by growth of our Electrophysiology business unit, led by our Farapulse™ Pulsed Field Ablation System, continued market penetration of Left Atrial Appendage Closure (LAAC) procedures with our WATCHMAN FLX™ LAAC Device and our WATCHMAN FLX™ Pro LAAC Device, as well as our coronary therapies franchise led by the recent U.S. launch of our AGENT™ Drug-Coated Balloon.

Peripheral Interventions 

Our Peripheral Interventions business develops and manufactures products to diagnose and treat peripheral arterial and venous diseases, as well as products to diagnose, treat and ease various forms of cancer. Net sales of Peripheral Interventions products of $656 million during the first quarter of 2025 represented 14 percent of our consolidated net sales. Peripheral Interventions net sales increased $83 million, or 14.4 percent, during the first quarter of 2025, compared to the prior year period. During the first quarter of 2025, this increase included operational net sales growth of 15.8 percent and the negative impact of 140 basis points from foreign currency fluctuations, compared to the prior year period. Operational net sales growth during the first quarter of 2025 included organic net sales growth of 7.4 percent and the positive impact of 840